These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9668298)

  • 1. Modulation of experimental autoimmune myasthenia gravis by recombinant fragments of the human acetylcholine receptor.
    Souroujon MC; Barchan D; Fuchs S
    Ann N Y Acad Sci; 1998 May; 841():572-5. PubMed ID: 9668298
    [No Abstract]   [Full Text] [Related]  

  • 2. Antigen-specific modulation of experimental myasthenia gravis: nasal tolerization with recombinant fragments of the human acetylcholine receptor alpha-subunit.
    Barchan D; Souroujon MC; Im SH; Antozzi C; Fuchs S
    Proc Natl Acad Sci U S A; 1999 Jul; 96(14):8086-91. PubMed ID: 10393952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nasal administration of synthetic acetylcholine receptor T epitopes affects the immune response to the acetylcholine receptor and prevents experimental myasthenia gravis.
    Karachunski PI; Ostlie NS; Okita DK; Conti-Fine BM
    Ann N Y Acad Sci; 1998 May; 841():560-4. PubMed ID: 9668295
    [No Abstract]   [Full Text] [Related]  

  • 4. Prevention of experimental autoimmune myasthenia gravis by manipulation of the immune network with a complementary peptide for the acetylcholine receptor.
    Araga S; LeBoeuf RD; Blalock JE
    Proc Natl Acad Sci U S A; 1993 Sep; 90(18):8747-51. PubMed ID: 8378359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of experimental autoimmune myasthenia gravis by major histocompatibility complex class II competitor peptides results not only in a suppressed but also in an altered immune response.
    Wauben MH; Hoedemaekers AC; Graus YM; Wagenaar JP; van Eden W; de Baets MH
    Eur J Immunol; 1996 Dec; 26(12):2866-75. PubMed ID: 8977279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.
    Atassi MZ; Oshima M; Deitiker P
    Crit Rev Immunol; 2001; 21(1-3):1-27. PubMed ID: 11642597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphocyte activation in experimental autoimmune myasthenia gravis.
    De Baets MH; Einarson B; Lindstrom JM; Weigle WO
    J Immunol; 1982 May; 128(5):2228-35. PubMed ID: 6977589
    [No Abstract]   [Full Text] [Related]  

  • 8. Modulation of the anti-acetylcholine receptor response and experimental autoimmune myasthenia gravis by recombinant fragments of the acetylcholine receptor.
    Barchan D; Asher O; Tzartos SJ; Fuchs S; Souroujon MC
    Eur J Immunol; 1998 Feb; 28(2):616-24. PubMed ID: 9521072
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences.
    Karachunski PI; Ostlie NS; Okita DK; Conti-Fine BM
    J Clin Invest; 1997 Dec; 100(12):3027-35. PubMed ID: 9399949
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depletion of CD8+ T cells suppresses the development of experimental autoimmune myasthenia gravis in Lewis rats.
    Zhang GX; Ma CG; Xiao BG; Bakhiet M; Link H; Olsson T
    Eur J Immunol; 1995 May; 25(5):1191-8. PubMed ID: 7774622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of experimental autoimmune myasthenia gravis by a monoclonal antibody to a complementary peptide for the main immunogenic region of the acetylcholine receptors.
    Araga S; Galin FS; Kishimoto M; Adachi A; Blalock JB
    J Immunol; 1996 Jul; 157(1):386-92. PubMed ID: 8683141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cells from normal and myasthenic individuals recognize the human acetylcholine receptor: heterogeneity of antigenic sites on the alpha-subunit.
    Melms A; Malcherek G; Gern U; Wiethölter H; Müller CA; Schoepfer R; Lindstrom J
    Ann Neurol; 1992 Mar; 31(3):311-8. PubMed ID: 1379027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization of bm12 mice with high doses of acetylcholine receptor overcomes their resistance to experimental autoimmune myasthenia gravis.
    Karachunski PI; Ostlie NS; Lei S; Okita DK; Lindstrom JM; Conti-Fine BM
    Ann N Y Acad Sci; 1998 May; 841():555-9. PubMed ID: 9668294
    [No Abstract]   [Full Text] [Related]  

  • 14. T cell reactivity to acetylcholine receptor in rats orally tolerized against experimental autoimmune myasthenia gravis.
    Wang ZY; Qiao J; Melms A; Link H
    Cell Immunol; 1993 Dec; 152(2):394-404. PubMed ID: 8258147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymphocyte responsiveness to acetylcholine receptor in rats with experimental autoimmune myasthenia gravis.
    Noguchi SA; Drachman DB; Adams RN; Hirsch RL
    Ann Neurol; 1980 Jul; 8(1):32-7. PubMed ID: 7406445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of experimental autoimmune myasthenia gravis in rats by fetal alpha-fetoprotein-rich fractions.
    Brenner T; Zielinski A; Argov Z; Abramsky O
    Tumour Biol; 1984; 5(5):263-74. PubMed ID: 6085187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epitope spreading in experimental autoimmune myasthenia gravis.
    Agius MA; Twaddle GM; Fairclough RH
    Ann N Y Acad Sci; 1998 May; 841():365-7. PubMed ID: 9668260
    [No Abstract]   [Full Text] [Related]  

  • 18. Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor.
    Loutrari H; Kokla A; Tzartos SJ
    Eur J Immunol; 1992 Sep; 22(9):2449-52. PubMed ID: 1516631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Injection of inactive Bordetella pertussis and complete Freund's adjuvant with Torpedo californica AChR increases the occurrence of experimental autoimmune myasthenia gravis in C57BL/6 mice.
    Maruta T; Oshima M; Mosier DR; Atassi MZ
    Autoimmunity; 2017 Aug; 50(5):293-305. PubMed ID: 28548588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel immunotoxin: a fusion protein consisting of gelonin and an acetylcholine receptor fragment as a potential immunotherapeutic agent for the treatment of Myasthenia gravis.
    Hossann M; Li Z; Shi Y; Kreilinger U; Büttner J; Vogel PD; Yuan J; Wise JG; Trommer WE
    Protein Expr Purif; 2006 Mar; 46(1):73-84. PubMed ID: 16230023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.